What's Happening?
A study has demonstrated that maternal vaccination with a live-attenuated Rift Valley fever virus (RVFV) can protect offspring through immune transfer. The RVFV-delNSs/NSm vaccine, which is highly immunogenic and DIVA compatible, was shown to provide complete protection against RVF in several animal species. The study highlights the importance of maternal vaccination in transferring immunity to offspring, particularly in species where newborns rely on colostrum for maternal antibodies. The findings suggest that maternal vaccination could be a viable strategy to protect both pregnant animals and their offspring from RVF.
AD
Why It's Important?
Rift Valley fever poses a significant threat to both human and animal health, particularly in Africa. The ability to protect offspring through maternal vaccination could reduce the disease burden in livestock, improve agricultural stability, and prevent spillover into human populations. This approach aligns with the One Health model, emphasizing the interconnectedness of animal, human, and environmental health. The study's findings could lead to new vaccination strategies that enhance public health and support economic stability in regions affected by RVF.
What's Next?
Further research is needed to evaluate the safety and effectiveness of RVFV vaccines during pregnancy in various animal models. Studies focusing on the timing and dosage of maternal vaccination could optimize immune transfer and protection. Collaboration with veterinary and public health organizations could facilitate the development and implementation of maternal vaccination programs. The potential for extending this strategy to other diseases and species may also be explored, broadening the impact of maternal vaccination on global health.
